China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Bumped Up to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of China SXT Pharmaceuticals (NASDAQ:SXTC) from a sell rating to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings upgraded China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

China SXT Pharmaceuticals Price Performance

China SXT Pharmaceuticals stock opened at $3.25 on Friday. China SXT Pharmaceuticals has a twelve month low of $3.07 and a twelve month high of $8,375,880.00. The firm has a 50 day moving average price of $175.63 and a 200-day moving average price of $16,540.14. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.94 and a quick ratio of 7.76.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals, Inc is a pharmaceutical company focused on the development, manufacture and sale of traditional Chinese medicine (TCM) products. The company produces herbal formulations intended for use in the treatment and management of various health conditions, as well as products positioned for general wellness and health maintenance.

Its product portfolio includes prescription medicines, over-the-counter medicines and dietary supplements. The company’s offerings are based on traditional Chinese medicinal practices and may be provided in forms such as herbal extracts, pills and other finished formulations.